TMJ Disorders Market to See a Major Financial Boost in the Forecast by 2027

Posted by vinit sawant on April 29th, 2021

Market Highlights

TMJ disorders are commonly known as temporomandibular joint and muscle disorders. This is a medical condition that causes dysfunction and pain in the jaw joint and the muscles that control jaw movement.

It is more common in women than men. Factors that drive the market growth are rising introduction and rapid adoption of advanced treatments, easy availability of medicines, increasing prevalence of TMJ disorders, and rise in healthcare spending worldwide.

Global TMJ Disorders Market Size is expected to register a CAGR of 4.18% during the forecast period and is expected to hit USD 650.07 Million by 2027.

Segment Analysis

Global TMJ Disorders Market, based on Type, is segmented into Myofascial Pain, Internal Derangement (ID), and Osteoarthritis. The global TMJ disorders market, based on treatment, is segmented into medication, therapies, surgical, and others. The medication segment is further sub-segmented into pain relievers, anti-inflammatories, tricyclic antidepressants, muscle relaxants, and others. Based on end user, the global TMJ disorders market is categorized into hospitals and clinics, ambulatory surgery centers, academic institutes, and others

Key Players

MRFR recognizes the following companies as the Key Players in the global TMJ Disorders market— Abbott Laboratories, Sun Pharmaceutical Industries Limited, Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd, Allergan, Bayer AG, Zydus Cadila, Mylan NV, Novartis International AG, and Jubilant Life Sciences Limited.

Key Findings of the Study

• Global TMJ Disorders Market was valued at USD 474.61 Million and is expected to register a CAGR of 4.18% during the assessment period.
• The Americas accounted for the largest global market share, which is majorly attributed to the introduction and rapid adoption of advanced treatments in the region.
• Based on type, the myofascial pain segment accounted for the largest market share of 39.73% in 2019.
• Based on treatment, the medication segment dominated the market with a value of 46.31% in 2019.
• Based on end-user, the hospitals & clinics segment dominated the market with a value of 51.9% in 2019.